<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4744">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753102</url>
  </required_header>
  <id_info>
    <org_study_id>CLR_10_19</org_study_id>
    <secondary_id>CTRI/2012/09/002983</secondary_id>
    <nct_id>NCT01753102</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Of Spil's Estradiol Vaginal Tablet</brief_title>
  <official_title>EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Pharmaceutical Industries Limited</source>
  <oversight_info>
    <authority>India: Drugs Controller General of India</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estradiol vaginal tablet is a tablet which hydrates upon contact with moisture, releasing
      17ß-estradiol.

      The estradiol in estradiol vaginal tablet is chemically and biologically identical to the
      endogenous human estradiol and is therefore classified as a human estrogen.

      The purpose of this study is to demonstrate clinical endpoint bioequivalence of SPIL's
      Estradiol vaginal tablet, 10mcg estradiol to the reference listed drug (Vagifem®)which is
      approved and marketed in the US.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Estradiol vaginal tablet is indicated for use in the treatment of symptoms of atrophic
      vaginitis due to estrogen deficiency.

      This is a randomized, observer blind, parallel groups, active and placebo controlled study
      to test the clinical endpoint bioequivalence of test product (Estradiol vaginal tablet,
      10mcg of Sun Pharmaceutical Industries Ltd. India) relative to reference (Vagifem®,
      Estradiol vaginal tablet, 10mcg estradiol of Novo Nordisk) in treatment of vulvar and
      vaginal atrophy.

      The patients will be administered with one tablet intravaginally daily for 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Vaginal pH</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms of vulvar and vaginal atrophy</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Each subject will specify identified most bothersome symptoms vaginal dryness, vaginal and/or vulvar irritation/ itching, dysuria, vaginal pain associated with sexual activity, vaginal bleeding associated with sexual activity) and self-evaluate the symptom on a pre-defined scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">405</enrollment>
  <condition>Vulvar Atrophy</condition>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference: Estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravaginal self-administration of study medication once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <description>one tablet will be inserted daily for 14 days</description>
    <arm_group_label>Estradiol</arm_group_label>
    <arm_group_label>Reference: Estradiol</arm_group_label>
    <other_name>Vagifem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman

          -  At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal
             atrophy

          -  ≤ 5% superficial cells on vaginal smear cytology

          -  Vaginal pH &gt; 5.0

        Exclusion Criteria:

          -  Consumption of estrogen alone or estrogen/progestin containing drug products.

          -  Allergy to estradiol or related products

          -  History of breast cancer and significant risk factors for endometrial cancer

          -  Abnormal genital bleeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Atul Raut, MD, PhD</last_name>
    <phone>91 22 66455645</phone>
    <phone_ext>752</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Biniwale Clinic Pvt. Ltd,</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 29, 2013</lastchanged_date>
  <firstreceived_date>December 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Estradiol</keyword>
  <keyword>Vulvar atrophy</keyword>
  <keyword>vaginal atrophy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
